Brief: Betterlife Pharma Advanced In IND-enabling Studies For BETR-001
01/05/2024 13:35
May 1 (Reuters) - BetterLife Pharma Inc BETR.CD :
* BETTERLIFE PHARMA INC: ADVANCED IN IND-ENABLING STUDIES
FOR
BETR-001, A NON-HALLUCINOGENIC DERIVATIVE OF LSD
* BETTERLIFE PHARMA INC: IND-ENABLING METABOLISM AND
GENOTOXICITY
GLP STUDIES HAVE BEEN INITIATED.
Source text for Eikon: ID:nGNX32j0qf
Further company coverage: BETR.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BetterLife Pharma
See all newsBrief: Betterlife Pharma Provides Scientific Update On Neuroplastogenic Activity Of BETR-001
Brief: Betterlife Pharma Advanced In IND-enabling Studies For BETR-001
Brief: BetterLife Announces Closing Of $1.168 Million Convertible Debentures To Further Advance IND-Enabling Studies Of Its Non-Hallucinogenic LSD-Based Drug Candidate BETR-001
Brief: Omineca Announces $2 Mln Brokered Financing Of Flow-Through Units
Brief: Betterlife Announces Pricing Of Proposed Offering Of Units